Exhibit 99 Movano Health Reports Q2 2024 Financial Results and Provides Business Update Prepares for September 17, 2024, Evie Ring back in stock date Announces brand partnership with digital creator Heidi D'Amelio Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. – August 14, 2024 – Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the succes ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) Delaware (Stateofincorporation) | --- | --- | |-------|-----------------------| | | 82-42 ...

Prepares for September 17, 2024, Evie Ring back in stock date Announces brand partnership with digital creator Heidi D'Amelio Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that i ...

Dr. Rodriguez and Mr. Hughes will join Movano Health CEO John Mastrototaro and Movano Health Chief Commercial Officer Michael Soule for the event. Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensiv ...

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications "Utilizing deep learning is significantly better than standard techniques as it is the optimal solution for removing the effects of motion, eliminating the noise and motion artifacts in the optical signal," said Leabman. "We believe that this is a first of its kind implementation and an innovation that has the potential to enhance the reliability of wearable health monitors, providing users with m ...

could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Delaware 82-4233771 Identification No.) 6800 K ...

Movano Inc. (NASDAQ:MOVE) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants John Mastrototaro - Chief Executive Officer Michael Soule - Vice President of Business Development Jeremy Cogan - Chief Financial Officer Stacy Salvi - Vice President of Products and Strategy Tyla Bucher - Chief Marketing Officer Michael Leabman - Founder and CTO Conference Call Participants Operator Greetings and welcome to the Movano Health Q1 2024 Earnings Call. At this time, all participants are in a ...

Exhibit 99.1 First Quarter 2024 and Recent Financial Highlights Movano Health Reports Q1 2024 Financial Results and Provides Business Update Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance process Plans launch of Evie Med and focuses on B2B opportunities Plans arterial blood pressure study for June Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. – May 15, 2024 – Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported first quarter 2024 results ...

Unlocking business-to-business opportunities with Evie Med, Movano Health's ring pulse oximeter, remains a key priority for the Company. PLEASANTON, Calif., May 9, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company's first commercial medical device, the Evie Med Ring p ...